MathioudakisAG
@MathioudakisAG
Followers
837
Following
1K
Media
111
Statuses
825
NIHR Clinical Lecturer in Respiratory Medicine @OfficialUoM Precision medicine in #COPD & #AECOPD, Clinical #Trials, #Guidelines, #EBM.
Manchester, England
Joined June 2011
🚨Rethinking Blood Eosinophils (BEC) for Assessing #ICS Response in #COPD: A Post-Hoc Analysis from #FLAME. - BEC change during ICS treatment predicts treatment response to ICS in COPD. - BEC measured on ICS treatment misclassify 9% of patients. @journal_CHEST
@ManchesterBRC
1
4
6
🚀 Fully Funded PhD @OfficialUoM! Use big data & AI to detect COPD earlier and reduce #HealthInequalities. Train in #RespiratoryEpidemiology, #DigitalHealth, #Epidemiology & #DataScience Starts Oct 2026. 📩 Contact me for details https://t.co/8p2zs7AgM8
findaphd.com
PhD Project - (Bicentenary) Bridging the gap: Using routinely collected clinical data for earlier detection and treatment optimisation of chronic airway diseases. at The University of Manchester,...
0
0
3
📢 Advancing Precision Medicine in Airway Diseases Dr Alexander Mathioudakis @MathioudakisAG is driving personalised care in COPD through data-driven research, identifying treatable traits and guiding therapies for maximal benefit. His work integrates large datasets, trial
0
1
3
Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial. https://t.co/8gJnutqQxJ
@mathioudakisag
3
15
32
📢 Future Leaders 2025 – Dr Alexander G. Mathioudakis We’re proud to spotlight Dr Alexander Mathioudakis, Senior Lecturer at The University of Manchester and Consultant Respiratory Physician, as a touchRESPIRATORY Future Leader 2025. 🌍🫁 Read Q&A: 👉 https://t.co/OH1mUfqCyx
0
4
5
The new European Respiratory Journal impact factor is 21. Ranked #2 across all resp journals Thank you to the incredible @donsin4 , all authors, our outstanding editors and journal staff ♥️ @ERSpublications @EuroRespSoc IF for selected respiratory journals below
6
21
98
We are pleased to announced our new 2024 Journal Impact Factors: European Respiratory Journal, 21.0 (Q1) European Respiratory Review, 10.4 (Q1) ERJ Open Research, 4.0 (Q1) Breathe, 3.4 (Q2) Thank you to all our editors for their work to achieve these!
1
14
41
📅ERS President Prof. Silke Ryan has opened the ‘ERS Presidential Summit on Prevention: Improving Respiratory Health in Europe’ – welcoming both professional/patient stakeholders for an in-depth look at respiratory disease prevention.
1
3
12
👉 Ex-smokers with high BEC (≥200) do benefit from LABA+ICS 🚭 But current smokers? Minimal ICS response. 📊 Smoking status modifies ICS efficacy @JensUlrikJensen
@victoriachgr
@ManchesterBRC
@UoM_DIIIRM
0
2
3
🔥 Our new analysis from the #FLAMEtrial - just published @ThoraxBMJ: 📉 Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: Insights from the FLAME trial. https://t.co/mmI5p1ub3I
1
3
7
It was a great pleasure to speak about career pathways in airway diseases at the @RSMResp #CareersDay. Great event! Thank you @RSMResp and @DrSachinAnanth for the invitation!
Our @RoySocMed Respiratory Careers Day is underway! @MathioudakisAG discusses a career in airways disease
0
0
2
ERS is delighted to announce the 2025 Fellows of ERS (FERS) awardees ⭐ The FERS award recognises outstanding contributions in research, education & clinical leadership. Find out more: https://t.co/VR60FoBEVd
0
2
16
🌟Delighted and honoured to be selected as a Fellow of the @EuroRespSoc (#FERS)! ERS has supported me throughout my clinical, research, and professional journey. Grateful for the recognition—and excited to give back. Congrats to all 2025 Fellows! 🔗
ersnet.org
ERS is an international membership organisation that unites physicians, health professionals, scientists and other experts working in respiratory medicine.
0
0
12
🚨 Submit your articles at our Research Topic @Frontiers in Allergy "Biologics for Airway Diseases: From Bench to Bedside" 🔬🧬💉 Topic Editors: Lena Uller, Dina Visca, @ngpdoc, @MathioudakisAG 🗓️ Submissions now open! 🔗 https://t.co/CyOu4p8dhm
frontiersin.org
Biologics represent a breakthrough in the management of airway diseases, offering precision treatments that target specific immune pathways. This special iss...
0
2
4
JUST PUBLISHED: our article on the highlights of @EuroRespSoc Assembly 5 at ERS 2024 Makes me very excited for #ERSCongress 2025! https://t.co/iRmpt6Awwg
0
1
7
Pleasure to speak at the @RespirEffect Summit today about our work on viruses in asthma Thank you to the organisers for the conference award
1
2
11
0
0
2
🌟We hope that ICS‑RECODE will contribute to more informed, personalized treatment decisions in COPD care. Stay tuned for updates as we move forward with this research.
1
1
3
🤝 Multistakeholder collaboration is central—integrating input from clinicians, researchers, and patient representatives to ensure real‑world relevance and drive evidence‑based COPD management. #PatientInvolvement #COPDResearch
1
0
1
🔍 Focused on blood eosinophils as a key biomarker, ICS‑RECODE will evaluate which patients reap maximum benefits from ICS—balancing improved outcomes against potential risks like pneumonia. #Biomarkers #RespiratoryResearch
1
0
0
🛠️Using a two‑stage meta‑analysis approach aligned with Cochrane and GRADE guidelines, we will rigorously re‑evaluate both efficacy and safety outcomes of ICS. This method helps ensure robust assessment of treatment×covariate interactions.
1
0
1